EC Number   |
Application |
Reference |
|---|
    2.4.2.28 | analysis |
methylthioadenosine phosphorylase protein expression may be a predictive marker of interferon therapy resistance in patients with melanoma and disease progression |
671628 |
| 2.4.2.28 | diagnostics |
methylthioadenosine phosphorylase protein expression may be a predictive marker of interferon therapy resistance in patients with melanoma and disease progression |
671628 |
| 2.4.2.28 | drug development |
combination of 5'-methylthioadenosine with clinical cancer drugs 5-fluorouracil or 6-thioguanine, in the treatment of MTAP-negative tumors, may produce a significantly improved therapeutic index |
706428 |
| 2.4.2.28 | drug development |
loss of MTAP activity in a subset of chordomas suggests that this group of patients may benefit from chemoselective inhibition of the de novo purine synthesis pathway. Purine synthesis inhibitors may be considered for chordoma patients with MTAP-deficient tumours |
705308 |
| 2.4.2.28 | drug development |
potential of MTAN as target for bacterial anti-infective drug design |
-, 700355 |
| 2.4.2.28 | medicine |
enzyme is a potential chemotherapeutic target |
637551 |
| 2.4.2.28 | medicine |
gene is linked to the important tumor suppressor gene p16INK4A, enzyme is of key importance in defining the chromosomal area homozygously deleted in a large number of human tumors, absence of enzyme activity only in malignant cells is of great value in developing selective antitumor therapeutic strategies |
637546 |
| 2.4.2.28 | medicine |
possibility of targeting the enzyme in the design of an enzyme-selective therapy for patients with T-cell acute lymphoblastic leukemia and other enzyme-deficient malignancies |
637548 |
